No stranger to headwinds, bluebird runs into two PDUFA delays unrelated to new safety issues
Bluebird bio hit another speed bump Tuesday in its efforts to win its first FDA approvals as regulators pushed back two PDUFA dates.
The FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
